Yong Shao Yap’s Post

View profile for Yong Shao Yap, graphic

Final year student at Monash University Malaysia | Degree in Medical Bioscience

Hoping this launch of the new drug, tafenoquine co-administered with cholroquinone can help eliminate the endemic faced by the countries affected. Even though the target for this drug is specific for Plasmodium vivax, there are many more types Plasmodium that causes malaria like P. ovale, P. falciparum, P. knowlesi and P. malariae. These are the most common types of Plasmodium species known to cause malaria. Looking forward for future R&D of new drugs in targeting these parasites. Well done GSK! #eliminatemalaria

View organization page for GSK, graphic

4,070,434 followers

📢 Brazil and Thailand become the first malaria-endemic countries to launch new single-dose relapse prevention medicine for Plasmodium vivax (P. vivax) malaria    P. vivax is the dominant malaria parasite in many countries outside of sub-Saharan Africa and is characterised by clinical relapses. Without treatment for the latent liver-stage infection, patients experience repeated bouts of illness, imposing significant physical, economic, and social burdens on both individuals and communities. Relapses also increase the disease burden and the potential for onward transmission, ultimately impeding global efforts to eliminate malaria.     Developed through a longstanding partnership Medicines for Malaria Venture, tafenoquine, co-administered with chloroquine, offers a new potential treatment option for vulnerable populations who are disproportionately affected by this disease.     By continuing to invest in global health R&D, strengthening healthcare systems, and enabling access to healthcare in lower-income countries, together with our partners we can help change the trajectory of malaria.    #ChangeTheTrajectory #Malaria #GlobalHealth #ZeroMalaria 

To view or add a comment, sign in

Explore topics